Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 4/20 | 0.35 |
| ▸ | KDM1B | Q8NB78 | 2/20 | 0.35 |
| ▸ | CYP11B2 | P19099 | 3/20 | 0.33 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.32 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.32 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.32 |
| ▸ | IGF1R | P08069 | 1/20 | 0.31 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.31 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.31 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25928266 | 0.77 | CYP11B1 (0.34) | CYP11B2IGF1RCYP11B1 | |
| SCHEMBL21608929 | 0.75 | CHRM4 (0.32) | CYP11B2TLR9TLR8TLR7CYP11B1 | |
| SCHEMBL25928308 | 0.70 | KDM1A (0.32) | KDM1AKDM1BCHRM4 | |
| SCHEMBL25928305 | 0.70 | CHRM4 (0.31) | CHRM4 | |
| SCHEMBL25928274 | 0.70 | PTGS1 (0.32) | CYP11B2IGF1RCYP11B1 | |
| SCHEMBL16132537 | 0.69 | L3MBTL1 (0.38) | CHRM4 | |
| SCHEMBL23612780 | 0.67 | CNR2 (0.33) | IGF1R | |
| SCHEMBL25928229 | 0.67 | CNR2 (0.37) | — | |
| SCHEMBL25928325 | 0.67 | — | — | |
| SCHEMBL25928312 | 0.67 | ADORA2A (0.33) | CYP11B2CYP11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11718626-B2 | Macrocyclic compounds for treatment of medical disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2023-08-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11718626-B2 | Macrocyclic compounds for treatment of medical disorders | CFD, TFPI, CFH | KDM1A 4766/4885KDM1B 4745/4885CYP11B2 196/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.